TICKERNERD
Menu
IMCCIMCCHealthcare · Drug Manufacturers - Specialty & Generic

IMCC Stock Forecast: IM Cannabis Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.11
−1.84% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$1.8M
Ticker Nerd rank
19 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−8.2%
1M
−18.2%
YTD
−91.9%
1Y
−94.9%
From 52W high
−95.4%
From 52W low
+6.7%
$0.11
$2.44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMCC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IM Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Accruals
97
Issuance
53
Revisions
25
Volatility
21
Quality
19
Value
12
Growth
4
Momentum
0

Size (100): Smaller than most of the companies we track.

Momentum (0): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMCC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50$2.00$2.50Oct 25Jan 26Apr 26Jul 26IMCC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Dec 2021Roth CapitalInitiatesBuy—
5 Oct 2021Roth CapitalInitiatesBuy—
10 June 2021Alliance Global PartnersInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMCC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IMCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

IM Cannabis Corp. (IMCC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
0.0×

Cheaper than 98% of US stocks

Price / book
−0.1×

Cheaper than 93% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−40.2%

Higher than 7% of US stocks

Earnings growth (YoY)
−30.6%

Higher than 15% of US stocks

Gross margin
16.3%

Higher than 16% of US stocks

Operating margin
−27.5%

Higher than 20% of US stocks

Net margin
−39.1%

Higher than 12% of US stocks

Returns & dividend
Return on equity
313.1%

Higher than 99% of US stocks

Return on assets
−18.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IMCC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
IMCCIM Cannabis Corp.$1.8M
19
SHPHShuttle Pharmaceuticals Holdings, Inc.$2.4M
16
PRFXPRF Technologies Ltd.$3.0M
3
SBFMSunshine Biopharma, Inc.$4.5M
62
INMInMed Pharmaceuticals, Inc.$4.8M
23
SXTCChina Sxt Pharmaceuticals, Inc.$5.4M
9
YCBDcbdMD, Inc.$5.7M
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IM Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMCC news & analysis

IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance

PRNewsWire · 18 Aug 2026neutral

IM Cannabis Corp. announced that its board approved a 30:1 consolidation of its common shares, with an expected effective date of August 27, 2026, to help the company meet Nasdaq's minimum bid price requirement.

Why it matters — The share consolidation is a corporate action aimed at supporting IMCC's continued Nasdaq listing compliance, which watchers would track for its potential impact on the stock's trading structure.

IM Cannabis Leverages Restructuring Deal to Reduce Financial Strain

Benzinga · 17 Aug 2026neutral

IM Cannabis Corp. agreed on Monday to divest its subsidiary IMC Holdings Ltd. to Slil.com Holding Ltd. as part of a restructuring deal aimed at reducing financial strain.

Why it matters — IMCC watchers would care because this divestiture is part of a restructuring effort intended to ease the company's financial burden.

IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets

PRNewsWire · 17 Aug 2026neutral

IM Cannabis Corp. announced it has entered into a definitive share purchase agreement dated August 16, 2026, with Slil.com Holding Ltd. and I.M.C. to sell IMC Holdings and its European-focused assets. The transaction is expected to improve shareholders' equity by approximately CAD$3 million.

Why it matters — This divestiture of European assets could reshape IMCC's business structure and improve its shareholders' equity position.

IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results

PRNewsWire · 13 Aug 2026neutral

IM Cannabis Corp. announced its financial results for the second quarter and first half of 2026, covering the three and six months ended June 30, 2026. The results are reported in Canadian dollars, as stated in the company's August 13, 2026 press release.

Why it matters — The financial results provide a key update on IMCC's performance for the first half of the fiscal year, which investors and analysts use to assess the company's financial health and operational progress.

IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing

PRNewsWire · 7 Aug 2026neutral

IM Cannabis Corp. announced the closing of a US$250,000 convertible note financing in a private placement with an institutional investor, issuing a note with a 10% original issuance discount under a note purchase agreement dated August 6, 2026.

Why it matters — IMCC watchers would care because this raises additional capital for the company through a private placement, though it also adds dilution and indebtedness via the convertible note.

FAQ

Frequently asked questions about IMCC stock

Is IMCC stock a buy right now?

Of the 1 analysts covering IM Cannabis Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IM Cannabis Corp. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMCC?

As at 22 Aug 2026, IM Cannabis Corp. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the IMCC stock forecast for 2030?

No analyst covering IM Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMCC are extrapolating price history, which says nothing about the business.

How has IMCC stock performed over the past year?

IM Cannabis Corp. returned -94.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IM Cannabis Corp. do?

Im Cannabis Corp. is a globally recognized player in the cannabis industry, specializing in the cultivation, processing, and distribution of medical and recreational cannabis products.

What is the latest news on IMCC?

The most recent item we track (PRNewsWire, 18 Aug 2026): "IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance". IM Cannabis Corp. announced that its board approved a 30:1 consolidation of its common shares, with an expected effective date of August 27, 2026, to help the company meet Nasdaq's minimum bid price requirement.

Company

About IM Cannabis Corp.

Im Cannabis Corp. is a globally recognized player in the cannabis industry, specializing in the cultivation, processing, and distribution of medical and recreational cannabis products. With operations particularly focused in Israel, Canada, and Germany, the company leverages its multi-national presence to drive innovation in cannabis research and development. Im Cannabis Corp. plays a pivotal role in advancing cannabis as a viable pharmaceutical alternative, working alongside health professionals to improve patient care. The firm is deeply involved in scientific studies and the development of new strains, aiming to enhance the efficacy and safety of cannabis products. As the industry experiences rapid growth and increasing regulatory acceptance worldwide, Im Cannabis Corp. is positioned at the forefront of this evolution, contributing to the expansion and quality assurance of cannabis offerings across different markets. Its strategic partnerships and comprehensive supply chain management underscore its commitment to leadership in this burgeoning sector.

CEO Mr. Oren Shuster · 44 employees · Canada · https://imcannabis.com